How to buy Taiwan Liposome Company stock (TLC)

Taiwan Liposome Company is a biotechnology business based in the US. Taiwan Liposome Company shares (TLC) are listed on the NASDAQ and all prices are listed in US Dollars.

Our top picks for where to buy Taiwan Liposome Company stock

Buy Taiwan Liposome Company stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Taiwan Liposome Company stock price (NASDAQ: TLC)

Use our graph to track the performance of TLC stocks over time.

Taiwan Liposome Company shares at a glance

• Key figures

Information last updated 2021-11-07.

52-week range	$0.00 - $0.00
50-day moving average more info button	$7.16
200-day moving average more info button	$6.37
Wall St. target price	$9.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.67

Is it a good time to buy Taiwan Liposome Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Taiwan Liposome Company financials

Revenue TTM	$276 million
Gross profit TTM	$101.9 million
Return on assets TTM	-34.73%
Return on equity TTM	-108.77%
Profit margin	-283.11%
Book value	$4.19
Market Capitalization more info button	$302.8 million

TTM: trailing 12 months

Taiwan Liposome Company share dividends

We're not expecting Taiwan Liposome Company to pay a dividend over the next 12 months.

Have Taiwan Liposome Company's shares ever split?

Taiwan Liposome Company's shares were split on a 506:503 basis on 9 June 2020 . So if you had owned 503 shares the day before before the split, the next day you'd have owned 506 shares. This wouldn't directly have changed the overall worth of your Taiwan Liposome Company shares – just the quantity. However, indirectly, the new 0.6% lower share price could have impacted the market appetite for Taiwan Liposome Company shares which in turn could have impacted Taiwan Liposome Company's share price.

Taiwan Liposome Company share price volatility

Over the last 12 months, Taiwan Liposome Company's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Taiwan Liposome Company's is 0.7972. This would suggest that Taiwan Liposome Company's shares are less volatile than average (for this exchange).

Taiwan Liposome Company overview

Taiwan Liposome Company, Ltd. , a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III clinical trial for the treatment of knee osteoarthritis pain. The company's product candidates also comprise TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that has completed Phase II clinical trial to treat post-surgical pain; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma; and TLC19 that is in Phase I clinical trial to treat COVID-19. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.

Frequently asked questions

What percentage of Taiwan Liposome Company is owned by insiders or institutions?
Currently 0.124% of Taiwan Liposome Company shares are held by insiders and 1.757% by institutions. When does the fiscal year end for Taiwan Liposome Company?
Taiwan Liposome Company's fiscal year ends in December. Where is Taiwan Liposome Company based?
Taiwan Liposome Company's address is: No. 3 Yuanqu Street, Taipei, Taiwan, 11503 What is Taiwan Liposome Company's ISIN number?
Taiwan Liposome Company's international securities identification number is: US8740381020 What is Taiwan Liposome Company's CUSIP number?
Taiwan Liposome Company's Committee on Uniform Securities Identification Procedures number is: 874038102